Keywords
Nilotinib
Dasatinib
Chronic myeloid leukemia
Chronic phase
Clinical effect
Submitted : 2022-06-27
Accepted : 2022-07-12
Published : 2022-07-27
Abstract
The study was conducted to explore the effect of imatinib, nilotinib, and dasatinib in the treatment of chronic myeloid leukemia (CML) patients. Around 66 patients with CML in chronic phase were selected, subsequently the patients were subdivided into 3 groups with 22 patients in each group: Group A were treated with imatinib; Group B were treated with nilotinib; and Group C were treated with dasatinib. The study showed that, at 18 months of treatment, compared with group A, the molecular biology remission rates of group B and group C were significantly higher, p<0.05; at 6 months and 18 months of treatment, compared with group A, the complete cytogenetic remission rates of group B and group C were significantly higher, p<0.05; and compared with group A, the incidences of vomiting, headache and edema in groups B and C were significantly lower, p<0.05. However, no significant different p>0.05 were observed in the complete hematologic remission rates, and the incidences of neutropenia and thrombocytopenia among the three groups. In summary, nilotinib and dasatinib are effective in the treatment of patients with CML in the chronic phase, which is significantly better than imatinib treatment.
References
Liu Q, Xu J, Wu J, et al., 2022, Efficacy and Influencing Factors of Second-Line Nilotinib and Third-Line Dasatinib on Chronic Myeloid Leukemia that Failed First- and Second-Line Therapy. Chinese Journal of Experimental Hematology, 30(1): 30–35. http://doi.org/10.19746/j.cnki.issn1009-2137.2022.01.006
Wang X, Zhang Y, Ning H, et al., 2020, Rapid Health Technology Assessment of Dasatinib in the Treatment of Chronic Myeloid Leukemia. China Modern Applied Pharmacy, 37(14): 1755–1759. http://doi.org/10.13748/j.cnki.issn1007-7693.2020.14.017
Wang L, Sun W, Yang Z, et al., 2020, Application of HPLC-MS/MS Method in Monitoring Blood Concentration of CML Patients Treated with Imatinib, Dasatinib and Nilotinib. Laboratory Medicine and Clinic, 17(14): 1992–1996. http://doi.org/10.3969/j.issn.1672-9455.2020.14.014
Yang L, Liu W, Sun Q, et al., 2020, Predictive Value of NK Cell Absolute Value on TKI Treatment Response in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase. Journal of Nanjing Medical University (Natural Science Edition), 40(7): 991–995. http://doi.org/10.7655/NYDXBNS20200711
Yang F, Zhang L, Shen Y, et al., 2020, Research Progress of BCR-ABL Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Chronic Myeloid Leukemia. China Journal of New Drugs and Clinical Medicine, 39(2): 71–75. http://doi.org/10.14109/j.cnki.xyylc.2020.02.02
Li Z, Ge X, 2020, Analysis of Clinical Features and Treatment of Chronic Myeloid Leukemia. Chinese Medicine, 15(2): 280–283. http://doi.org/10.3760/j.issn.1673-4777.2020.02.029
Bai Y, Wang X, Zhang Y, 2020, Rapid Health Technology Evaluation of Nilotinib in the Treatment of Chronic Myeloid Leukemia. China Journal of New Drugs, 29(1): 113–117. http://doi.org/10.3969/j.issn.1003-3734.2020.01.017
Wang L, 2020, Comparison of Dasatinib and Nilotinib in the Treatment of Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia. China Health Nutrition, 30(6): 266.
Yuan T, Lai Y, Qin Y, et al., 2020, Efficacy and Influencing Factors of Nilotinib and Dasatinib as Second- and Third-Line Drugs in Patients with Chronic Myeloid Leukemia in Chronic Phase and Accelerated Phase. Zhonghua Blood Journal of Science, 41(2):93–99. http://doi.org/10.3760/cma.j.issn.0253-2727.2020.02.002
Li S, Xu W, Ding J, 2021, et al., Comparison of the Efficacy and Safety of Imatinib and Cytarabine Combined with Imatinib Monotherapy in the Treatment of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. China Practical Medical Journal, 48(24): 86–89.
Flavin Su, 2020, Early Efficacy of Nilotinib and Imatinib in the Treatment of Chronic Myeloid Leukemia. Shenzhen Journal of Integrative Medicine, 30(6): 146–147.
Shi D, Qin Y, Lai Y, et al., 2020, Distribution and Influencing Factors of BCR-ABL Kinase Domain Mutations in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia. Chinese Journal of Hematology, 41(6): 469–476.
Zou W, 2021, Comparison of the Efficacy of Imatinib in the Treatment of Chronic Myeloid Leukemia in Different Stages. China Practical Medicine, 16(4): 124–126.
Jin Y, 2020, Effects of Imatinib on the Expression of Serum COX-2, bFGF, and TGF-?1 in Patients with Chronic Myeloid Leukemia in the Early Stage. Medical Theory and Practice, 33(9): 1450–1452.
Ye Y, Lv X, Li H, 2021, Efficacy Observation of Chinese-Made Imatinib in the Treatment of Newly Diagnosed Chronic Myeloid Leukemia in the Real World. Chinese Journal of Experimental Hematology, 29(2): 456–461.
Xu X, Xing H, Han L, et al., 2020, Single-Center Real-World Clinical Study of Domestic Imatinib in the Treatment of Chronic Myeloid Leukemia. Lymphoma, 29(10): 586–589.
Mei S, Xing Y, Liu Lu, et al., 2021, Efficacy of Psychological Counseling Combined with Original or Domestic Imatinib Mesylate in Patients with Chronic Myeloid Leukemia and its Effects on Depression and Anxiety. International Psychiatry Journal of Science, 48(5): 905–908.
Yao Lu, 2021, Clinical Effect of Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia. Zhonghua Health Care, 39(3): 181–182.
Wu W, 2021, Research Progress on the Immunomodulatory Effect of Imatinib Mesylate on Chronic Myeloid Leukemia. Journal of Clinical Rational Drugs, 14(11): 179–181.
Du H, 2020, Clinical Efficacy of Cytarabine Combined with Imatinib in the Treatment of Chronic Myeloid Leukemia. Chinese Journal of Recuperation Medicine, 29(3): 321–323.